Medizinonline Medizinonline
  • News
    • News
    • Market & Medicine
  • Patients
    • Disease patterns
    • Diagnostics
    • Therapy
  • Partner Content
    • Dermatology
      • Atopic dermatitis and psoriasis news
      • Dermatology News
    • Diabetes
      • Dia-Month Club – Type 2 Diabetes
      • Diabetes in Motion
      • Diabetes Podcasts
    • Gastroenterology
      • IBD matters
      • Forum Gastroenterology
      • Ozanimod: ulcerative colitis
      • Reflux Update
    • Immunology
      • Primary immunodeficiency – exchange of experience
    • Vaccinate
      • Herpes zoster
    • Infektiologie
    • Neurology
      • EXPERT ULTRASONIC: Introduction to ultrasound-guided injection
      • MS News
      • MS Therapy in Transition
    • Oncology
      • Swiss Oncology in motion
    • Orthopedics
      • Osteoporosis in motion
    • Phytotherapie
    • Practice Management
      • Aargau Cantonal Bank
      • Claraspital
    • Psychiatry
      • Geriatric Psychiatry
    • Rheumatology
  • Departments
    • Allergology and clinical immunology
    • General Internal Medicine
    • Anesthesiology
    • Angiology
    • Surgery
    • Dermatology and venereology
    • Endocrinology and Diabetology
    • Nutrition
    • Gastroenterology and Hepatology
    • Genetics
    • Geriatrics
    • Gynecology
    • Hematology
    • Infectiology
    • Cardiology
    • Nephrology
    • Neurology
    • Emergency and intensive care medicine
    • Nuclear Medicine
    • Oncology
    • Ophthalmology
    • ORL
    • Orthopedics
    • Pediatrics
    • Pharmacology and toxicology
    • Pharmaceutical medicine
    • Phlebology
    • Physical medicine and rehabilitation
    • Pneumology
    • Prevention and health care
    • Psychiatry and psychotherapy
    • Radiology
    • Forensic Medicine
    • Rheumatology
    • Sports Medicine
    • Traumatology and trauma surgery
    • Tropical and travel medicine
    • Urology
    • Dentistry
  • CME & Congresses
    • CME continuing education
    • Congress Reports
    • Congress calendar
  • Practice
    • Noctimed
    • Practice Management
    • Jobs
    • Interviews
  • Log In
  • Register
  • My account
  • Contact
  • English
    • Deutsch
    • Français
    • Italiano
    • Português
    • Español
  • Publications
  • Contact
  • Deutsch
  • English
  • Français
  • Italiano
  • Português
  • Español
Subscribe
Medizinonline Medizinonline
Medizinonline Medizinonline
  • News
    • News
    • Market & Medicine
  • Patienten
    • Krankheitsbilder
    • Diagnostik
    • Therapie
  • Partner Content
    • Dermatology
      • Atopic dermatitis and psoriasis news
      • Dermatology News
    • Diabetes
      • Dia-Month Club – Type 2 Diabetes
      • Diabetes in Motion
      • Diabetes Podcasts
    • Gastroenterology
      • IBD matters
      • Forum Gastroenterology
      • Ozanimod: ulcerative colitis
      • Reflux Update
    • Immunology
      • Primary immunodeficiency – exchange of experience
    • Vaccinate
      • Herpes zoster
    • Infektiologie
    • Neurology
      • EXPERT ULTRASONIC: Introduction to ultrasound-guided injection
      • MS News
      • MS Therapy in Transition
    • Oncology
      • Swiss Oncology in motion
    • Orthopedics
      • Osteoporosis in motion
    • Phytotherapie
    • Practice Management
      • Aargau Cantonal Bank
      • Claraspital
    • Psychiatry
      • Geriatric Psychiatry
    • Rheumatology
  • Departments
    • Fachbereiche 1-13
      • Allergology and clinical immunology
      • General Internal Medicine
      • Anesthesiology
      • Angiology
      • Surgery
      • Dermatology and venereology
      • Endocrinology and Diabetology
      • Nutrition
      • Gastroenterology and Hepatology
      • Genetics
      • Geriatrics
      • Gynecology
      • Hematology
    • Fachbereiche 14-26
      • Infectiology
      • Cardiology
      • Nephrology
      • Neurology
      • Emergency and intensive care medicine
      • Nuclear Medicine
      • Oncology
      • Ophthalmology
      • ORL
      • Orthopedics
      • Pediatrics
      • Pharmacology and toxicology
      • Pharmaceutical medicine
    • Fachbereiche 26-38
      • Phlebology
      • Physical medicine and rehabilitation
      • Phytotherapy
      • Pneumology
      • Prevention and health care
      • Psychiatry and psychotherapy
      • Radiology
      • Forensic Medicine
      • Rheumatology
      • Sports Medicine
      • Traumatology and trauma surgery
      • Tropical and travel medicine
      • Urology
      • Dentistry
  • CME & Congresses
    • CME continuing education
    • Congress Reports
    • Congress calendar
  • Practice
    • Noctimed
    • Practice Management
    • Jobs
    • Interviews
Login

Sie haben noch keinen Account? Registrieren

  • Guselkumab in psoriatic arthritis

Early response predicted

    • Dermatology and venereology
    • Market & Medicine
    • Rheumatology
    • RX
    • Studies
  • 3 minute read

Recent analyses of a heterogeneous group of patients with active psoriatic arthritis (PsA) show that early treatment response with respect to skin psoriasis and enthesitis is a predictor of sustained treatment success. The IL-23 inhibitor guselkumab has been approved in Switzerland for the treatment of PsA since 2021.

A recently published post-hoc analysis of the phase III DISCOVER-1 and DISCOVER-2 trials (box) analyzed data from adult patients with active psoriatic arthritis (PsA). This indicates that early treatment response to guselkumab (Tremfya®) predicts longer-term clinical response, including disease remission at week 52 [1–3]. According to another post-hoc analysis of the DISCOVER-2 substudy, in a heterogeneous population of biologics-naïve patients treated with Tremfya®, several PsA-related endpoints were maintained over two years, including minimal disease activity (MDA), appearance-free skin (IGA 0), and disappearance of dactylitis, independent of baseline patient characteristics and dosing regimen [4].

Several relevant endpoints were maintained

The new analyses of the DISCOVER-1 and -2 data show the following [2]:

  • At week 24, early skin response was associated with a higher likelihood of achieving MDA (minimal disease activity), DAPSA (low disease activity in PsA), and DAPSA remission.
  • Early response of enthesitis was associated with a higher probability of achieving MDA, DAPSA, LDA (low disease activity), and disappearance of enthesitis or dactylitis.
  • DAPSA remission was achieved by a greater proportion of patients who had an early response of enthesitis, although this association was significant only at week 52.
  • Patients who showed an early response with respect to both psoriasis and enthesitis were more likely to achieve MDA, DAPSA LDA, and DAPSA remission.

In summary, these results underline the relevance of an early treatment response for the further course.

Long-term response across different PsA patient populations.

In another post-hoc analysis of the DISCOVER-2 trial data, the following results were obtained with treatment with Tremfya® in a heterogeneous population of adults with active PsA over two years [4]:

  • Several endpoints recommended by GRAPPA for PsA disease control were maintained, including ACR50 and ACR70, IGA 0, resolution of dactylitis and enthesitis, and MDA response. This proved to be independent of the following patient characteristics at baseline: Gender, body mass index (BMI), number of swollen joints (SJC), number of painful joints (TJC), duration of PsA, C-reactive protein (CRP), affected body surface area (BSA), and Psoriasis Area and Severity Index (PASI).
  • At week 100, the stringent endpoints were sustained in multiple domains (MDA response, IGA 0, and resolution of dactylitis), regardless of the use of concomitant therapies (nbDMARD and methotrexate).
  • No consistent differences in the proportion of responders were observed between patient subgroups with sufficient sample size or between Tremfya® dosing regimens.
  • The results of this post-hoc analysis support the long-term efficacy (Week 100) of Tremfya® across the spectrum of active PsA disease domains and diverse PsA patient populations.

Source: Janssen-Cilag

Literature:

  1. ” New TREMFYA® (guselkumab) Post-Hoc Analysis Reveals Early Efficacy Predicted Longer-Term Efficacy And Sustained Achievement Among A Diverse Active Psoriatic Arthritis Patient Population,” Janssen, Nov. 11, 2022.
  2. Coates L, et al: Early Skin and Early Enthesitis Responses in Psoriatic Arthritis Patients Treated with Guselkumab Associate with Long-term Response: Post Hoc Analysis Through 2 Years of a Phase 3 Study. (ABSTRACT #2115). Presented at ACR Convergence 2022, November 10-14.
  3. Drug Information, www.swissmedicinfo.ch, (last accessed Dec. 07, 2022).
  4. Ritchlin C, et al: Stringent Disease Activity Control at 2 Years Across Psoriatic Arthritis Domains Irrespective of Baseline Characteristics in Patients Treated with Guselkumab: Post Hoc Analysis of a Phase 3, Randomized, Double-blind, Placebo-controlled Study. (ABSTRACT #2112). Presented at ACR Convergence 2022, November 10-14.
  5. Clinicaltrials.gov: A Study Evaluating the Efficacy and Safety of Guselkumab Administered Subcutaneously in Participants With Active Psoriatic Arthritis Including Those Previously Treated With Biologic Anti-Tumor Necrosis Factor (TNF) Alpha Agent(s) (DISCOVER-1). https://clinicaltrials.gov/ct2/show/NCT03162796, (last accessed 07.12.2022)
  6. Clinicaltrials.gov: A Study Evaluating the Efficacy and Safety of Guselkumab Administered Subcutaneously in Participants With Active Psoriatic Arthritis (DISCOVER-2). https://clinicaltrials.gov/ct2/show/NCT03158285, (last accessed 07.12.2022)

DERMATOLOGY PRACTICE 2022; 32(6): 29

Autoren
  • Mirjam Peter, M.Sc.
Publikation
  • DERMATOLOGIE PRAXIS
Related Topics
  • Address
  • discover
  • Enthesitis
  • GUSElkumab
  • IL-23
  • Janssen
  • Predictor
  • Psoriatic Arthritis
  • Skin psoriasis
  • treatment success
Previous Article
  • Heart failure

Tips and tricks in the family practice

  • RX
  • Cardiology
  • CME continuing education
  • General Internal Medicine
  • Surgery
  • Unkategorisiert
View Post
Next Article
  • KDIGO Guidelines 2022

Modern therapy can slow progression of diabetic nephropathy

  • Education
  • Endocrinology and Diabetology
  • General Internal Medicine
  • Nephrology
  • RX
  • Studies
  • Unkategorisiert
View Post
You May Also Like
View Post
  • 9 min
  • Chronic lung diseases

Sarcopenia and malnutrition in the context of pneumological rehabilitation

    • CME continuing education
    • General Internal Medicine
    • Geriatrics
    • Nutrition
    • Pneumology
    • RX
    • Sports Medicine
    • Studies
View Post
  • 17 min
  • Sleep-wake disorders in pneumology practice

Patience, knowledge and persistence in therapy

    • CME continuing education
    • General Internal Medicine
    • Neurology
    • Pneumology
    • RX
View Post
  • 19 min
  • Cardiovascular risk and obesity

Pathomechanisms, secondary prevention and treatment options

    • Cardiology
    • CME continuing education
    • Endocrinology and Diabetology
    • Nutrition
    • RX
    • Sports Medicine
    • Studies
    • Training with partner
View Post
  • 9 min
  • Oxidative stress and neurodegeneration

Insights and therapeutic strategies for Parkinson’s disease

    • Education
    • Neurology
    • Phytotherapy
    • RX
    • Studies
View Post
  • 4 min
  • Biologics for atopic dermatitis

Th2 cytokines in focus: proven and new targets

    • Allergology and clinical immunology
    • Congress Reports
    • Dermatology and venereology
    • Pharmacology and toxicology
    • RX
    • Studies
View Post
  • 3 min
  • Teens, Screen and Mental Health

How social media influences depression in young people

    • Education
    • Pediatrics
    • Prevention and health care
    • Psychiatry and psychotherapy
    • RX
View Post
  • 4 min
  • CHD: Management after revascularization

Individualization of antithrombotic therapy

    • Cardiology
    • Congress Reports
    • General Internal Medicine
    • RX
    • Studies
View Post
  • 30 min
  • Chemsex - MSM, sex, chrystal meth & co.

Medical and psychosocial perspectives

    • CME continuing education
    • General Internal Medicine
    • Infectiology
    • Pharmacology and toxicology
    • Prevention and health care
    • Psychiatry and psychotherapy
    • RX
Top Partner Content
  • Forum Gastroenterology

    Zum Thema
  • Herpes zoster

    Zum Thema
  • Dermatology News

    Zum Thema
Top CME content
  • 1
    Patience, knowledge and persistence in therapy
  • 2
    Sarcopenia and malnutrition in the context of pneumological rehabilitation
  • 3
    Medical and psychosocial perspectives
  • 4
    New nomenclature for non-alcoholic fatty liver disease
  • 5
    Examinations and considerations before therapy

Newsletter

Sign up and stay up to date

Subscribe
Medizinonline
  • Contact
  • General terms and conditions
  • Imprint

Input your search keywords and press Enter.